Open Access

Silymarin‑mediated regulation of the cell cycle and DNA damage response exerts antitumor activity in human hepatocellular carcinoma

  • Authors:
    • Hong Cui
    • Tie‑Ling Li
    • Hai‑Feng Guo
    • Jia‑Liang Wang
    • Ping Xue
    • Ying Zhang
    • Jing‑Hui Fan
    • Zhi‑Ping Li
    • Yue‑Juan Gao
  • View Affiliations

  • Published online on: November 15, 2017     https://doi.org/10.3892/ol.2017.7425
  • Pages: 885-892
  • Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A novel module‑search algorithm method was used to screen for potential signatures and investigate the molecular mechanisms of inhibiting hepatocellular carcinoma (HCC) growth following treatment with silymarin (SM). The modules algorithm was used to identify the modules via three major steps: i) Seed gene selection; ii) module search by seed expansion and entropy minimization; and iii) module refinement. The statistical significance of modules was computed to select the differential modules (DMs), followed by the identification of core modules using the attract method. Pathway analysis for core modules was implemented to identify the biological functions associated with the disease. Subsequently, results were verified in an independent sample set using reverse transcription polymerase chain reaction (RT‑PCR). In total, 18 seed genes and 12 DMs (modules 1‑12) were identified. The core modules were isolated using gene expression data. Overall, there were 4 core modules (modules 11, 5, 6 and 12). Additionally, DNA topoisomerase 2‑binding protein 1 (TOPBP1), non‑structural maintenance of chromosomes condensing I complex subunit H, nucleolar and spindle associated protein 1 (NUSAP1) and cell division cycle associated 3 (CDCA3) were the initial seed genes of module 11, 5, 6 and 12, respectively. Pathway results revealed that cell cycle signaling pathway was enriched by all core modules simultaneously. RT‑PCR results indicated that the level of CDCA3, TOPBP1 and NUSAP1 in SM‑treated HCC samples was markedly decreased compared with that in non‑SM‑treated HCC. No statistically significant difference between the transcriptional levels of CDCA3 in SM‑treated and non‑treated HCC groups was identified, although CDCA3 expression was increased in the treated group compared with the untreated group. Furthermore, although the expression level of TOPBP1 and NUSAP1 in the SM‑treated group was decreased compared with that in the normal group, no significant difference was observed. From the results of the present study it can be inferred that TOPBP1, NUSAP1 and CDCA3 of the core modules may serve notable functions in SM‑associated growth suppression of HCC.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cui H, Li TL, Guo HF, Wang JL, Xue P, Zhang Y, Fan JH, Li ZP and Gao YJ: Silymarin‑mediated regulation of the cell cycle and DNA damage response exerts antitumor activity in human hepatocellular carcinoma. Oncol Lett 15: 885-892, 2018
APA
Cui, H., Li, T., Guo, H., Wang, J., Xue, P., Zhang, Y. ... Gao, Y. (2018). Silymarin‑mediated regulation of the cell cycle and DNA damage response exerts antitumor activity in human hepatocellular carcinoma. Oncology Letters, 15, 885-892. https://doi.org/10.3892/ol.2017.7425
MLA
Cui, H., Li, T., Guo, H., Wang, J., Xue, P., Zhang, Y., Fan, J., Li, Z., Gao, Y."Silymarin‑mediated regulation of the cell cycle and DNA damage response exerts antitumor activity in human hepatocellular carcinoma". Oncology Letters 15.1 (2018): 885-892.
Chicago
Cui, H., Li, T., Guo, H., Wang, J., Xue, P., Zhang, Y., Fan, J., Li, Z., Gao, Y."Silymarin‑mediated regulation of the cell cycle and DNA damage response exerts antitumor activity in human hepatocellular carcinoma". Oncology Letters 15, no. 1 (2018): 885-892. https://doi.org/10.3892/ol.2017.7425